EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial delivery (RAPPORT)

Michelle Bardgett, Marie Falahee, Gwenda Simons, John D Isaacs, Luke Ouma, James MS Wason, Arthur G Pratt

Efficacy and Mechanism Evaluation · 2025

DOI: 10.3310/ashg1864 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Efficacy and Mechanism Evaluation, 2025. Verfasst von Michelle Bardgett und 6 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Efficacy and Mechanism Evaluation programme.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rheumatoid arthritis is a chronic disease of immune dysregulation affecting 1% of United Kingdom adults at an estimated cost to the taxpayer exceeding £5B per annum. Recently, enhanced pathophysiological understanding and a growing array of rational therapeutic candidates have converged on the potential to intercept rheumatoid arthritis before clinically manifest arthritis occurs, raising the possibility of delaying or even preventing disease. The National Institute for Health and Care Research Efficacy and Mechanism Evaluation Acceleration Award provided 12-month support to accelerate the development of an international precision medicine platform study, within remit of the Medical Research Council-National Institute for Health and Care Research Efficacy and Mechanism Evaluation Programme. To this end, Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial proposed a pan-European precision medicine platform trial for preventative interventions in people at risk of rheumatoid arthritis. Challenges of delivering a trial of this nature led by a United Kingdom Sponsor, as well as those specific to the delivery of Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial, were addressed.

Objectives

The overarching aim of Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial was to submit a stage 1 application for the Efficacy and Mechanism Evaluation call: 23/15 precision medicine platform studies to efficiently evaluate the efficacy of interventions. In delivering this, we met the following objectives: Understand optimal sponsorship, governance and funding models for international platform trials by synthesising relevant literature in the form of systematic review. Convene and engage an international at risk of rheumatoid arthritis Precision Platform Trial Management Group with expertise in the pathobiological understanding and therapeutic management of at risk of rheumatoid arthritis, as well as the design and delivery of interception trials, with a view to developing a master protocol. Convene and consult a Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial Public Advisory Group to directly inform trial design, including a strategy for mapping the level of rheumatoid arthritis progression risk to lifestyle and/or pharmacological interventions. Identify interventions to be evaluated in a platform trial, engaging appropriately with industry partners. Identify optimal clinical and/or immunological biomarkers for participant stratification. Outcomes Five work streams were set up to target delivery of the aforementioned objectives. A systematic review entitled ‘Operational complexities in international clinical trials: a systematic review of challenges and proposed solutions’ has been registered with the Open Science Framework, completed and submitted for publication. Linked to this, a working group was established to identify barriers and solutions to acting as Sponsor for Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial; purposeful interactions with European Union and United Kingdom partner sites helped prioritise governance and funding models to enable delivery, and have informed local standard operating procedures for sponsoring international trials. A patient and public involvement Advisory group was formed, and a series of events and programme of work undertaken to feed into all aspects of Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial. A range of potential interventions, non-pharmacological and pharmacological, were considered and prioritised for inclusion in Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial’s design. A funding framework supported by industry partners, incorporating one lifestyle and two drug interventions, was developed, along with a strategy for prioritising future interventions. A working group was furthermore convened for the management of biological samples to be collected for research in biomarker evaluations. A stage 1 application for the 23/15 Efficacy and Mechanism Evaluation call was submitted in May 2023.

Limitations

In its first iteration, the substantive clinical trial proposal proposed as a result of the Accelerator award reported herein was not funded by National Institute for Health and Care Research. In part this was due to the approach adopted to address the ‘precision medicine’ element of the brief. Other challenges include the assembly of geographically diverse patient partners for an international study given time constraints, and logistical complexity in international trial design. Future work Efforts to fund the work described in amended form are ongoing. Funding This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation programme as award number NIHR153955.

Förderung

  • Efficacy and Mechanism Evaluation programme

Zitieren

APA

Bardgett, M., Falahee, M., Simons, G., Isaacs, J. D., Ouma, L., Wason, J. M., & Pratt, A. G. (2025). Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial delivery (RAPPORT). Efficacy and Mechanism Evaluation. https://doi.org/10.3310/ashg1864

Vancouver

Bardgett M, Falahee M, Simons G, Isaacs JD, Ouma L, Wason JM, et al. Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial delivery (RAPPORT). Efficacy and Mechanism Evaluation. 2025. doi:10.3310/ashg1864

BibTeX
@article{Bardgett2025,
  author = {Bardgett, Michelle and Falahee, Marie and Simons, Gwenda and Isaacs, John D and Ouma, Luke and Wason, James MS and Pratt, Arthur G},
  title = {Rheumatoid Arthritis Prevention: catalysing PlatfORm Trial delivery (RAPPORT)},
  journal = {Efficacy and Mechanism Evaluation},
  year = {2025},
  doi = {10.3310/ashg1864}
}
Kostenlos starten →